← Back to Search

Other

MRX-2843 for Advanced Refractory Cancer

Phase 1
Waitlist Available
Led By Donald Harvey
Research Sponsored by Meryx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Nonsterilized males who are sexually active with a female of childbearing potential must agree to use an acceptable method of effective contraception
Must not have
Subject has a history of Type 1 Diabetes (T1D) or is considered at high risk for T1D
Subject has not fully recovered to baseline from toxicity due to all prior therapies
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug to see if it is safe and works well against cancer that has come back or does not respond to other treatments.

Who is the study for?
Adults with advanced solid tumors that have relapsed or spread, who've tried at least one treatment without success. They must be over 18, able to take oral meds, and not pregnant or breastfeeding. Participants need normal organ function tests and agree to use effective contraception during the trial.
What is being tested?
The study is testing MRX-2843's safety and how it moves through the body (pharmacokinetics) in people with stubborn cancers that haven't responded well to other treatments. It's an early-stage trial where everyone gets MRX-2843.
What are the potential side effects?
Specific side effects of MRX-2843 aren't listed but may include typical reactions seen with cancer drugs such as nausea, fatigue, blood count changes, liver issues, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I am a man who can father children and will use birth control.
Select...
I am not pregnant, not breastfeeding, and my pregnancy test was negative.
Select...
My cancer is confirmed and can be measured or evaluated.
Select...
I've had one treatment for my advanced illness and there are no approved treatments left.
Select...
I agree to use two forms of birth control if I can have children and am sexually active.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have Type 1 Diabetes or am at high risk for it.
Select...
I still feel side effects from my previous cancer treatments.
Select...
I had surgery less than a month ago or have ongoing wound issues.
Select...
I have or might have an autoimmune disease.
Select...
I need to take certain blood thinners.
Select...
My high blood pressure is not under control.
Select...
I have or might have retinitis pigmentosa.
Select...
I have a serious illness that is not under control.
Select...
I have been diagnosed with chronic active hepatitis B or C.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRX-2843Experimental Treatment1 Intervention
MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD

Find a Location

Who is running the clinical trial?

Meryx, Inc.Lead Sponsor
1 Previous Clinical Trials
50 Total Patients Enrolled
Donald HarveyPrincipal InvestigatorEmory University

Media Library

MRX-2843 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03510104 — Phase 1
Cancer Research Study Groups: MRX-2843
Cancer Clinical Trial 2023: MRX-2843 Highlights & Side Effects. Trial Name: NCT03510104 — Phase 1
MRX-2843 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03510104 — Phase 1
~1 spots leftby Feb 2025